Cite

HARVARD Citation

    Usmani, S. et al. (n.d.). P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. HemaSphere. p. 19. [Online]. 
  
Back to record